A registry study on the collection of data regarding disease progression, treatment methods, and clinical outcomes in HIV-associated lymphomas

In HIV infection, a person becomes infected with the HI virus (human immunodeficiency virus), which leads to the destruction of certain immune cells. AIDS refers to the advanced stage of the disease, when the body’s defenses are severely weakened by the HIV infection, leading to serious health problems such as severe infections and cancers. Thanks to modern antiretroviral combination therapies (cART), survival rates and treatment outcomes for HIV-positive patients have improved significantly. Nevertheless, the risk of certain diseases, such as lymphomas, remains elevated. Lymphomas develop due to the uncontrolled proliferation of abnormal lymphocytes. These occur more frequently in people with HIV because the cancer cells can multiply uncontrollably when the immune system is weakened. Typical symptoms include swollen lymph nodes, fever, or fatigue. Common HIV-associated lymphomas include, among others, diffuse large B-cell lymphoma and Burkitt lymphoma.

The goal of the IN030121 study is to systematically collect data on the characteristics, therapies, and treatment outcomes of patients with HIV-associated lymphomas. Data will be collected both retrospectively and prospectively to assess, in particular, 2-year overall survival as well as progression-free survival—that is, survival without disease progression. The study aims to provide a better understanding of the course of the disease and the effectiveness of different treatment approaches, and to contribute in the long term to improving care and prognosis for HIV-positive patients with lymphoma. This is a purely observational study, which means that no additional interventions or treatments will be administered as part of the study. The required treatment for the lymphoma is not specifically defined, but it should be carried out in accordance with national or international guidelines. Overall, patients will be followed for a period of up to six years.

Adults diagnosed with HIV-associated lymphoma since 2010 are eligible to participate. The HIV diagnosis must have been made within three months of the lymphoma diagnosis.